Table 2. Summary of clinical outcomes of studies of Desvenlafaxine.

AUC: Area Under Curve, Des: Desvenlafaxine, IFN: Interferon, MDD: Major Depressive Disorder

Studies	Clinical outcomes
DeMartinis NA, et al., 2007 [11]	Des 100 and 400 mg helped with depression, 200 mg was not statistically significant compared to placebo.
Septien-Velez L, et al., 2007 [14]	Des 200 and 400 mg was effective compared to placebo for depressive symptoms and global functioning.
Boyer P, et al., 2015 [15]	Des 50 and 100 mg was effective compared to placebo for depressive symptoms and global functioning.
Liebowitz MR, et al., 2008 [16]	Des 50 and 100 mg was effective for depression, 100 mg was not statistically significant compared to placebo.
Feiger AD, et al., 2009 [6]	Des 200 and 400 mg was effective compared to placebo for depression but failed to reach statistical significance.
Dunlop BW, et al., 2011 [12]	Response and remission rates were 60% and 42% with des compared to 42% and 30% with placebo.
Clayton AD, et al., 2013 [10]	Des helped with depression and functional status among perimenopausal and post-menopausal women.
Ferguson JM, et al., 2012 [13]	High dose des was found to be safe and effective for MDD for up to a year.
Findling RL, et al., 2014 [20]	Des was effective for depression in short-term and long-term duration.
Findling RL, et al., 2016 [9]	Des was safe and well-tolerated in youth. The AUC was found to be linear with dosage.
Fábregas B, et al., 2014 [18]	Des helped with depression with full remission after IFN in one patient. In second patient, there was only minor improvement.
Feinberg SS, et al., 2010 [19]	Des 100 mg was effective for social phobia in a patient with Gilbert syndrome.